Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Michael Cipriano
The latest drug development news and highlights from our US FDA Performance Tracker.
Pink Sheet Podcast: New Opioid Approval Standards, Drug Pricing Legislation And New Paragraph IV Data
Pink Sheet Podcast: Insys Divests Opioids, Pretomanid's Advisory Committee Meeting, And Biosimilar User Fee Collections
In a letter to Senate HELP Committee chairman Sen. Lamar Alexander and ranking member Sen. Patty Murray, USP and other stakeholders are calling for the removal of language that would exclude biological products from requirements to follow USP quality standards.